Publicaciones en las que colabora con MARINA BERAZA MILLOR (13)

2024

  1. Gene therapy with lipid nanoparticles for Fabry disease: Leveraging E-selectin for targeted delivery to endothelial cells

    Journal of Drug Delivery Science and Technology, Vol. 99

  2. Systematic Review of Genetic Substrate Reduction Therapy in Lysosomal Storage Diseases: Opportunities, Challenges and Delivery Systems

    BioDrugs, Vol. 38, Núm. 5, pp. 657-680

  3. Targeting strategies with lipid vectors for nucleic acid supplementation therapy in Fabry disease: a systematic review

    Drug Delivery and Translational Research, Vol. 14, Núm. 10, pp. 2615-2628

2023

  1. Expression of a conserved sequence of SARS-CoV-2 for panβ-coronavirus vaccine development

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  2. Modelo SoTL para evaluar el aprendizaje basado en la investigación en el desarrollo de TFG sobre atención farmacéutica

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  3. Nanopartículas lipídicas funcionalizadas con GalNAc para suplementación génica: aplicación en la enfermedad de Fabry

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  4. Novel Golden Lipid Nanoparticles with Small Interference Ribonucleic Acid for Substrate Reduction Therapy in Fabry Disease

    Pharmaceutics, Vol. 15, Núm. 7

  5. siRNA vectors based on golden lipid nanoparticles for Fabry Disease

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

2022

  1. Galactomannan-Decorated Lipidic Nanocarrier for Gene Supplementation Therapy in Fabry Disease

    Nanomaterials, Vol. 12, Núm. 14

  2. mRNA delivery technologies: Toward clinical translation

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 207-293

2021

  1. Functionalised SLNs-based nanovectors for gene therapy in Fabry disease: The liver as an α-Galactosidase A factory

    RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 46-48

  2. Mrna-based nanomedicinal products to address corneal inflammation by interleukin-10 supplementation

    Pharmaceutics, Vol. 13, Núm. 9

  3. Substrate reduction therapy based on siRNA for Fabry Disease

    RESCIFAR Revista Española de Ciencias Farmacéuticas, Vol. 2, Núm. 2, pp. 84-86